Cargando…

Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma

Thyroid cancer is generally curable and, in many cases, can be completely treated, although it can sometimes recur after cancer therapy. Papillary thyroid cancer (PTC) is known as one of the most general subtypes of thyroid cancer, which take up nearly 80% of whole thyroid cancer. However, PTC may d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Hang-Seok, Kim, Yonjung, Lee, So Young, Yun, Hyeok Jun, Chang, Ho-Jin, Park, Ki Cheong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138651/ https://www.ncbi.nlm.nih.gov/pubmed/37108231 http://dx.doi.org/10.3390/ijms24087069

Ejemplares similares

Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer
por: Yun, Hyeok Jun, et al.
Publicado: (2022)

Potential Therapeutic Agents against Paclitaxel—And Sorafenib-Resistant Papillary Thyroid Carcinoma
por: Kim, Seok-Mo, et al.
Publicado: (2022)

Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer
por: Kim, Yuna, et al.
Publicado: (2023)

Papillary Thyroid Microcarcinomas Are Different from Latent Papillary Thyroid Carcinomas at Autopsy
por: Lee, Yong Sang, et al.
Publicado: (2014)

Aggressive Subtypes of Papillary Thyroid Carcinoma Smaller Than 1 cm
por: Lee, Jin Seok, et al.
Publicado: (2022)

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
por: Kim, Soo Young, et al.
Publicado: (2018)

Solitary lateral neck node metastasis in papillary thyroid carcinoma
por: Kim, Seok-Mo, et al.
Publicado: (2014)

Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models
por: Yun, Hyeok Jun, et al.
Publicado: (2021)

Coexistence of parathyroid adenoma and papillary thyroid carcinoma
por: Lee, Yong Sang, et al.
Publicado: (2011)

Impact of Age-Related Genetic Differences on the Therapeutic Outcome of Papillary Thyroid Cancer
por: Kim, Seok-Mo, et al.
Publicado: (2020)

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
por: Kim, Soo Young, et al.
Publicado: (2019)

Clinicopathological and Genetic Characteristics of Patients of Different Ages with Diffuse Sclerosing Variant Papillary Thyroid Carcinoma
por: Kim, Soo-Young, et al.
Publicado: (2023)

Ultrasonographic features and clinicopathologic characteristics of macrofollicular variant papillary thyroid carcinoma
por: Lee, Yong Sang, et al.
Publicado: (2018)

Lateral neck dissection for the treatment of synchronous and metachronous lateral neck metastasis of N1b papillary thyroid cancer
por: Yun, Hyeok Jun, et al.
Publicado: (2023)

Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer
por: Park, Ki Cheong, et al.
Publicado: (2017)

On-site ultrasound-guided localization for impalpable nodal recurrences in papillary thyroid carcinoma patients
por: Kim, Kuk-Jin, et al.
Publicado: (2013)

Adequacy and Effectiveness of Watson For Oncology in the Treatment of Thyroid Carcinoma
por: Yun, Hyeok Jun, et al.
Publicado: (2021)

Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib
por: Hussain, Syed Zubair, et al.
Publicado: (2013)

Overcoming the Limitations of Fine Needle Aspiration Biopsy: Detection of Lateral Neck Node Metastasis in Papillary Thyroid Carcinoma
por: Jun, Hak Hoon, et al.
Publicado: (2015)

Associations of the BRAF(V600E) Mutation with Sonographic Features and Clinicopathologic Characteristics in a Large Population with Conventional Papillary Thyroid Carcinoma
por: Park, Ah Young, et al.
Publicado: (2014)

Corrigendum to “Synergistic Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide and Sorafenib against Cancer Stem Cells, Anaplastic Thyroid Cancer” [Neoplasia 19 (2017) 145-153]
por: Park, Ki Cheong, et al.
Publicado: (2017)

Significance of the Extracapsular Spread of Metastatic Lymph Nodes in Papillary Thyroid Carcinoma
por: Park, Chang Ho, et al.
Publicado: (2015)

Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer
por: Danilovic, Debora L. S., et al.
Publicado: (2018)

PPARγ Targets-Derived Diagnostic and Prognostic Index for Papillary Thyroid Cancer
por: Kim, Jaehyung, et al.
Publicado: (2021)

Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer
por: Kim, Seok-Mo, et al.
Publicado: (2015)

The Clinical Significance of the Right Para-Oesophageal Lymph Nodes in Papillary Thyroid Cancer
por: Chang, Hojin, et al.
Publicado: (2015)

Aggressiveness of Differentiated Thyroid Carcinoma in Pediatric Patients Younger Than 16 years: A Propensity Score-Matched Analysis
por: Kim, Soo Young, et al.
Publicado: (2022)

Tumor Margin Histology Predicts Tumor Aggressiveness in Papillary Thyroid Carcinoma: A Study of 514 Consecutive Patients
por: Kim, Kuk-Jin, et al.
Publicado: (2011)

Accelerated Disease Progression after Discontinuation of Sorafenib in a Patient with Metastatic Papillary Thyroid Cancer
por: Yun, Kyung-Jin, et al.
Publicado: (2014)

Ultrasonographic Features of Papillary Thyroid Carcinoma in Patients with Graves' Disease
por: Chung, Jin Ook, et al.
Publicado: (2010)

2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells
por: Wang, Shuo-Yu, et al.
Publicado: (2015)

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
por: Takinami, Masaki, et al.
Publicado: (2020)

Targeting oncogenic Notch signaling with SERCA inhibitors
por: Pagliaro, Luca, et al.
Publicado: (2021)

Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations
por: Hahn, Soo Yeon, et al.
Publicado: (2017)

Prognosis of Anaplastic Thyroid Cancer with Distant Metastasis
por: Lee, Jin-Seok, et al.
Publicado: (2022)

A Scoring System for Prediction of Lateral Neck Node Metastasis from Papillary Thyroid Cancer
por: Jeong, Jong Ju, et al.
Publicado: (2011)

Papillary Thyroglossal Duct Cyst Carcinoma with Synchronous Occult Papillary Thyroid Microcarcinoma
por: Park, Min-Ho, et al.
Publicado: (2010)

Ultrasonographic Findings of Medullary Thyroid Carcinoma: a Comparison with Papillary Thyroid Carcinoma
por: Kim, Sung-Hun, et al.
Publicado: (2009)

XRCC1 Polymorphisms and Risk of Papillary Thyroid Carcinoma in a Korean Sample
por: Ryu, Ri A, et al.
Publicado: (2011)

Clinicopathological Significance of Minimal Extrathyroid Extension in Solitary Papillary Thyroid Carcinomas
por: Woo, Chang Gok, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bbcqaeij3mkspk8hmeihhl0jv2